Abstract
Get full access to this article
View all access options for this article.
References
1.
Nissen
SE
Wolski
K
Topol
EJ
. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus . JAMA 2005 ; 294 : 2581 –2586 .
2.
Nissen
SE
Wolski
K
. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes . N Engl J Med 2007 ; 356 : 2457 –2471 (Erratum in N Engl J Med 2007; 357: 100).
3.US Department of Health and Human Services, Food and Drug Administration and Center for Drug Evaluation and Research (CDER) . Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes , http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf
4.
Scirica
BM
Bhatt
DL
Braunwald
E
. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus . N Engl J Med 2013 ; 369 : 1317 –1326 .
5.European Medicines Agency . Publication and access to clinical-trial data . Draft for Public Consideration 24 June 2013 , http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/06/WC500144730.pdf